Nanologica Ab · OMXSTO:NICA
Nanologica Ab — Q1 2025 Earnings Presentation
25 slides from Nanologica Ab's earnings presentation, Apr 16, 2025
Slide 1: Interim Report Q1 2025
INTERIM REPORT Q1 2025 N A N O LO G I C A A B ( PU B L )
Slide 2: Financial Summary
FINANCIAL SUMMARY • Net sales for the first quarter amounted to SEK 10,751 thousand (5,037) • The operating loss amounted to SEK 9,241 thousand (15,331) • Loss after tax amounted to SEK 10,171 thousand (16,734) • Earnings per share before and after dilution were SEK -0.12 (-0.46) • Cash and cash equ
Slide 3: Sales Record for a Single Quarter
SALES RECORD FOR A SINGLE QUARTER The first quarter of the year meant a sales record for a single quarter for the company and a good start to the new year. The ongoing positive customer dialogues, combined with a continued stabilization of the production process, create good conditions for increased
Slide 4: CEO comments: product types and NLAB Siv
types that are mainly used in insulin purification. Adjustments mean that the majority now produced are product types that are primarily used in the purification of GLP-1 analogues. In summary, we are confident that we will deliver growth during the year, while it is likely that sales will vary from
Slide 5: This is Nanologica
THIS IS NANOLOGICA Better and cheaper medicine to a larger number of patients Nanologica is a Swedish life science tools company that provides consumables to pharmaceutical manufacturers. With a foundation in materials science and nanotechnology, the company has developed an expertise in chromatogra
Slide 6: Five Reasons to Invest in Nanologica
FIVE REASONS TO INVEST IN NANOLOGICA By developing chromatography products that enable pharmaceutical manufacturers to streamline their production and lower their production costs, Nanologica not only strives to create value for its shareholders, but also to contribute to more patients having access
Slide 7: Operating Income and Result; Investments, Liquidity and Financial Position
OPERATING INCOME AND RESULT INVESTMENTS, LIQUIDITY, AND Net sales for the first quarter amounted to SEK FINANCIAL POSITION 10,751 thousand (5,037), of which preparative Inventories amounted to SEK 28,635 thousand chromatography amounted to SEK 10,103 (5,034) compared to SEK 32,745 thousand at the th
Slide 8: Fluctuations in Revenue Generation; Employees and Organization
FLUCTUATIONS IN REVENUE Share-based incentive programs Warrant program 2023/2026 for management GENERATION team and The business generates revenue through the sale Each warrant of series TO 2023/2026 entitles the of products for preparative and analytical holder to subscribe for one new share in the
Slide 9: Future Prospects, External Factors, Risks and Uncertainties
FUTURE PROSPECTS EXTERNAL FACTORS This report contains forward-looking statements. Wars and geopolitical tensions continue to affect Actual outcomes may differ from these the world. During the quarter, this has not had any statements. Internal and external factors can direct impact on the company. H
Slide 10: Assurance
ASSURANCE The board of directors and the CEO provide their assurance that this interim report provides a fair and true overview of the parent company’s and the group’s operations, financial position, and results, and describes material risks and uncertainties faced by the parent company and the comp
Slide 11: Financial Reports and Notes
(SNA GICA FINANCIAL REPORTS AND NOTES
Slide 12: Consolidated Income Statement
CONSOLIDATED INCOME STATEMENT 2025 2024 2024 Amounts in TSEK Jan - Mar Jan - Mar Jan - Dec Net sales 10 751 5 037 14 538 Change in inventories, finished goods -3 578 2 061 18 163 Other operating income 74 25 633 Operating expenses Raw materials and consumables -6 003 -5 135 -28 408 Other external co
Slide 13: Consolidated Balance Sheet
CONSOLIDATED BALANCE SHEET 2025 2024 2024 Amounts in TSEK Mar 31 Mar 31 Dec 31 ASSETS Fixed assets Intangible fixed assets Capitalized expenditure for research and development and similar 13 622 20 141 15 234 Concessions, patents, licenses, trademarks and similar rights 0 1 423 0 Tangible fixed asse
Slide 14: Consolidated Statement of Changes in Equity
CONSOLIDATED STATEMENT OF CHANGES IN EQUITY 2025 2024 2024 Amounts in TSEK Jan - Mar Jan - Mar Jan - Dec Total equity at the beginning of the period 74 112 -1 898 -1 898 0 Profit/loss for the period -10 171 -16 769 -65 629 Other comprehensive income 0 0 0 Total comprehensive income for the period -1
Slide 15: Consolidated Cash Flow Statement
CONSOLIDATED CASH FLOW STATEMENT 2025 2024 2024 Amounts in TSEK Jan - Mar Jan - Mar Jan - Dec Operating activities Operating profit/loss -9 241 -15 331 -59 255 Adjustment for items not affecting cash flow 3 643 3 661 15 359 Valuation of other current assets -2 409 4 075 9 005 Reversal of provisions
Slide 16: Notes
NOTES NOTE 1 GENERAL INFORMATION This report covers the Swedish parent company Nanologica AB (publ), corporate registration number 556664- 5023, and its subsidiaries. The parent company is a limited liability company with its registered office in Stockholm, Sweden. The address of the main office is
Slide 17: Composition of Net Sales by Product, Region and Customer
2025 2024 2024 Composition of net sales, per product type (TSEK) Jan - Mar Jan - Mar Jan - dec Preparative chromatography 10 103 4 812 12 727 Analytical chromatography 647 224 808 Application development and similar services 0 0 1 003 Total 10 751 5 036 14 538 2025 2024 2024 Composition of net sales
Slide 18: Items Not Affecting Cash Flow; Related Party Transactions
NOTE 7 ITEMS NOT AFFECTING CASH FLOW 2025 2024 2024 Amounts in TSEK, group Jan - Mar Jan - Mar Jan - Dec Depreciations 3 643 3 653 14 119 Write-downs/disposals of intangible assets 0 0 1 426 Write-downs/disposals of fixed assets 0 0 3 Other items 0 8 -189 Total 3 643 3 661 15 359 2025 2024 2024 Amou
Slide 19: Definition of Key Figures
NOTE 10 DEFINITION OF KEY FIGURES The company presents certain financial measures that are not defined under IFRS. These alternative performance measures are used in internal reporting and as part of management's follow-up of the group's results and financial position. The company believes that thes
Slide 20: Group Quarterly Data
2025 2024 2024 Mar 31 Mar 31 Dec 31 A. Equity according to the balance sheet (TSEK) 63 940 11 075 74 112 B. Total assets according to balance sheet (TSEK) 125 087 107 924 143 099 A/B = Equity/assets ratio (%) 51 10 52 A. Equity according to the balance sheet (TSEK) 63 940 11 075 74 112 B. Number of
Slide 21: Income Statement for the Parent Company
INCOME STATEMENT FOR THE PARENT COMPANY 2025 2024 2024 Amounts in TSEK Jan - Mar Jan - Mar Jan - Dec Net sales 10 751 5 037 14 538 Change in inventories, finished goods -3 578 2 061 18 163 Other operating income 74 25 633 Operating expenses Raw materials and consumables -6 003 -5 135 -28 408 Other e
Slide 22: Balance Sheet for the Parent Company
BALANCE SHEET FOR THE PARENT COMPANY 2025 2024 2024 Amounts in TSEK Mar 31 31 Mar Dec 31 ASSETS Fixed assets Intangible assets Capitalized expenditure for research and development and similar 13 987 24 679 16 642 Concessions, patents, licenses, trademarks and similar rights 0 1 423 0 Total intangibl
Slide 23: Balance Sheet for the Parent Company (Equity and Liabilities)
BALANCE SHEET FOR THE PARENT COMPANY 2025 2024 2024 Amounts in TSEK Mar 31 31 Mar Dec 31 EQUITY AND LIABILITIES Equity Share capital 4 506 14 821 8 836 Fund for development expenditure 196 607 281 Total restricted equity 4 702 17 233 9 117 Non-restricted equity Share premium reserve 442 173 336 232
Slide 24: Parent Company Changes in Equity and Cash Flow Statement
STATEMENT OF CHANGES IN EQUITY FOR THE PARENT COMPANY 2025 2024 2024 Amounts in TSEK Jan - Mar Jan - Mar Jan - Dec Total equity at the beginning of the period 68 641 -6 940 -6 940 Total comprehensive income for the period -10 285 -16 904 -66 008 Off set loans through rights issue 0 6 176 22 125 Righ
Slide 25: Nanologica AB (publ) contact details
Nanologica AB (publ) Forskargatan 20 G, SE-151 36 Södertälje, Sweden Ph: +46 8 410 749 49 www.nanologica.com